Real-world change in annualized relapse rate and healthcare resource utilization following initiation of ofatumumab in people with multiple sclerosis

Authors
Category Primary study
JournalMult. Scler. Relat. Disord.
Year 2025
This article has no abstract
Epistemonikos ID: 3bb3954a46effa8ead65cca0ff5de3b311a4efd9
First added on: Sep 03, 2025